The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Lung Cancer Liquid Biops-Global Market Insights and Sales Trends 2024
Synopsis
The global Lung Cancer Liquid Biops market size is expected to reach US$ 1082 million by 2029, growing at a CAGR of 14.0% from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Liquid Biops in various end use industries. The expanding demands from the Hospitals and Clinics, Physicians'Office Laboratories and Clinical Diagnostic Laboratories,, are propelling Lung Cancer Liquid Biops market. Exosomes and RNA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTCs and ctDNA segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Lung Cancer Liquid Biops market, driven by demand from China, the second largest economy with some signs of stabilising, the Lung Cancer Liquid Biops market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Liquid Biops, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Liquid Biops market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Liquid Biops market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Liquid Biops sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Liquid Biops covered in this report include Biocept, EntroGen, Cynvenio Biosystems, Exosome Diagnostics, F. Hoffmann-La Roche, Clearbridge BioMedics, Bio-Rad Laboratories, Agena Bioscience and Cancer Genetics, etc.
The global Lung Cancer Liquid Biops market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocept
EntroGen
Cynvenio Biosystems
Exosome Diagnostics
F. Hoffmann-La Roche
Clearbridge BioMedics
Bio-Rad Laboratories
Agena Bioscience
Cancer Genetics
CellMax Life
Nateras
MedGenome
OncoDNA
Genomic Health
Trovagene
Fluxion Biosciences
Biodesix
Epic Sciences
Shuwen Biotech
Personal Genome Diagnostics
Predicine
Global Lung Cancer Liquid Biops market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Liquid Biops market, Segment by Type:
Exosomes and RNA
CTCs and ctDNA
Global Lung Cancer Liquid Biops market, by Application
Hospitals and Clinics
Physicians'Office Laboratories
Clinical Diagnostic Laboratories
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Liquid Biops companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Lung Cancer Liquid Biops market size is expected to reach US$ 1082 million by 2029, growing at a CAGR of 14.0% from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Liquid Biops in various end use industries. The expanding demands from the Hospitals and Clinics, Physicians'Office Laboratories and Clinical Diagnostic Laboratories,, are propelling Lung Cancer Liquid Biops market. Exosomes and RNA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTCs and ctDNA segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Lung Cancer Liquid Biops market, driven by demand from China, the second largest economy with some signs of stabilising, the Lung Cancer Liquid Biops market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Liquid Biops, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Liquid Biops market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Liquid Biops market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Liquid Biops sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Liquid Biops covered in this report include Biocept, EntroGen, Cynvenio Biosystems, Exosome Diagnostics, F. Hoffmann-La Roche, Clearbridge BioMedics, Bio-Rad Laboratories, Agena Bioscience and Cancer Genetics, etc.
The global Lung Cancer Liquid Biops market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocept
EntroGen
Cynvenio Biosystems
Exosome Diagnostics
F. Hoffmann-La Roche
Clearbridge BioMedics
Bio-Rad Laboratories
Agena Bioscience
Cancer Genetics
CellMax Life
Nateras
MedGenome
OncoDNA
Genomic Health
Trovagene
Fluxion Biosciences
Biodesix
Epic Sciences
Shuwen Biotech
Personal Genome Diagnostics
Predicine
Global Lung Cancer Liquid Biops market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Liquid Biops market, Segment by Type:
Exosomes and RNA
CTCs and ctDNA
Global Lung Cancer Liquid Biops market, by Application
Hospitals and Clinics
Physicians'Office Laboratories
Clinical Diagnostic Laboratories
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Liquid Biops companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Lung Cancer Liquid Biops
1.1 Lung Cancer Liquid Biops Market Overview
1.1.1 Lung Cancer Liquid Biops Product Scope
1.1.2 Lung Cancer Liquid Biops Market Status and Outlook
1.2 Global Lung Cancer Liquid Biops Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Lung Cancer Liquid Biops Market Size by Region (2018-2029)
1.4 Global Lung Cancer Liquid Biops Historic Market Size by Region (2018-2023)
1.5 Global Lung Cancer Liquid Biops Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Lung Cancer Liquid Biops Market Size (2018-2029)
1.6.1 North America Lung Cancer Liquid Biops Market Size (2018-2029)
1.6.2 Europe Lung Cancer Liquid Biops Market Size (2018-2029)
1.6.3 Asia-Pacific Lung Cancer Liquid Biops Market Size (2018-2029)
1.6.4 Latin America Lung Cancer Liquid Biops Market Size (2018-2029)
1.6.5 Middle East & Africa Lung Cancer Liquid Biops Market Size (2018-2029)
2 Lung Cancer Liquid Biops Market by Type
2.1 Introduction
2.1.1 Exosomes and RNA
2.1.2 CTCs and ctDNA
2.2 Global Lung Cancer Liquid Biops Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Lung Cancer Liquid Biops Historic Market Size by Type (2018-2023)
2.2.2 Global Lung Cancer Liquid Biops Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Lung Cancer Liquid Biops Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Lung Cancer Liquid Biops Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Lung Cancer Liquid Biops Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Lung Cancer Liquid Biops Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Lung Cancer Liquid Biops Revenue Breakdown by Type (2018-2029)
3 Lung Cancer Liquid Biops Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Physicians'Office Laboratories
3.1.3 Clinical Diagnostic Laboratories
3.2 Global Lung Cancer Liquid Biops Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Lung Cancer Liquid Biops Historic Market Size by Application (2018-2023)
3.2.2 Global Lung Cancer Liquid Biops Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Lung Cancer Liquid Biops Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Lung Cancer Liquid Biops Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Lung Cancer Liquid Biops Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Lung Cancer Liquid Biops Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Lung Cancer Liquid Biops Revenue Breakdown by Application (2018-2029)
4 Lung Cancer Liquid Biops Competition Analysis by Players
4.1 Global Lung Cancer Liquid Biops Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lung Cancer Liquid Biops as of 2022)
4.3 Date of Key Players Enter into Lung Cancer Liquid Biops Market
4.4 Global Top Players Lung Cancer Liquid Biops Headquarters and Area Served
4.5 Key Players Lung Cancer Liquid Biops Product Solution and Service
4.6 Competitive Status
4.6.1 Lung Cancer Liquid Biops Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Biocept
5.1.1 Biocept Profile
5.1.2 Biocept Main Business
5.1.3 Biocept Lung Cancer Liquid Biops Products, Services and Solutions
5.1.4 Biocept Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.1.5 Biocept Recent Developments
5.2 EntroGen
5.2.1 EntroGen Profile
5.2.2 EntroGen Main Business
5.2.3 EntroGen Lung Cancer Liquid Biops Products, Services and Solutions
5.2.4 EntroGen Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.2.5 EntroGen Recent Developments
5.3 Cynvenio Biosystems
5.3.1 Cynvenio Biosystems Profile
5.3.2 Cynvenio Biosystems Main Business
5.3.3 Cynvenio Biosystems Lung Cancer Liquid Biops Products, Services and Solutions
5.3.4 Cynvenio Biosystems Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.3.5 Exosome Diagnostics Recent Developments
5.4 Exosome Diagnostics
5.4.1 Exosome Diagnostics Profile
5.4.2 Exosome Diagnostics Main Business
5.4.3 Exosome Diagnostics Lung Cancer Liquid Biops Products, Services and Solutions
5.4.4 Exosome Diagnostics Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.4.5 Exosome Diagnostics Recent Developments
5.5 F. Hoffmann-La Roche
5.5.1 F. Hoffmann-La Roche Profile
5.5.2 F. Hoffmann-La Roche Main Business
5.5.3 F. Hoffmann-La Roche Lung Cancer Liquid Biops Products, Services and Solutions
5.5.4 F. Hoffmann-La Roche Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.5.5 F. Hoffmann-La Roche Recent Developments
5.6 Clearbridge BioMedics
5.6.1 Clearbridge BioMedics Profile
5.6.2 Clearbridge BioMedics Main Business
5.6.3 Clearbridge BioMedics Lung Cancer Liquid Biops Products, Services and Solutions
5.6.4 Clearbridge BioMedics Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.6.5 Clearbridge BioMedics Recent Developments
5.7 Bio-Rad Laboratories
5.7.1 Bio-Rad Laboratories Profile
5.7.2 Bio-Rad Laboratories Main Business
5.7.3 Bio-Rad Laboratories Lung Cancer Liquid Biops Products, Services and Solutions
5.7.4 Bio-Rad Laboratories Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.7.5 Bio-Rad Laboratories Recent Developments
5.8 Agena Bioscience
5.8.1 Agena Bioscience Profile
5.8.2 Agena Bioscience Main Business
5.8.3 Agena Bioscience Lung Cancer Liquid Biops Products, Services and Solutions
5.8.4 Agena Bioscience Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.8.5 Agena Bioscience Recent Developments
5.9 Cancer Genetics
5.9.1 Cancer Genetics Profile
5.9.2 Cancer Genetics Main Business
5.9.3 Cancer Genetics Lung Cancer Liquid Biops Products, Services and Solutions
5.9.4 Cancer Genetics Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.9.5 Cancer Genetics Recent Developments
5.10 CellMax Life
5.10.1 CellMax Life Profile
5.10.2 CellMax Life Main Business
5.10.3 CellMax Life Lung Cancer Liquid Biops Products, Services and Solutions
5.10.4 CellMax Life Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.10.5 CellMax Life Recent Developments
5.11 Nateras
5.11.1 Nateras Profile
5.11.2 Nateras Main Business
5.11.3 Nateras Lung Cancer Liquid Biops Products, Services and Solutions
5.11.4 Nateras Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.11.5 Nateras Recent Developments
5.12 MedGenome
5.12.1 MedGenome Profile
5.12.2 MedGenome Main Business
5.12.3 MedGenome Lung Cancer Liquid Biops Products, Services and Solutions
5.12.4 MedGenome Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.12.5 MedGenome Recent Developments
5.13 OncoDNA
5.13.1 OncoDNA Profile
5.13.2 OncoDNA Main Business
5.13.3 OncoDNA Lung Cancer Liquid Biops Products, Services and Solutions
5.13.4 OncoDNA Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.13.5 OncoDNA Recent Developments
5.14 Genomic Health
5.14.1 Genomic Health Profile
5.14.2 Genomic Health Main Business
5.14.3 Genomic Health Lung Cancer Liquid Biops Products, Services and Solutions
5.14.4 Genomic Health Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.14.5 Genomic Health Recent Developments
5.15 Trovagene
5.15.1 Trovagene Profile
5.15.2 Trovagene Main Business
5.15.3 Trovagene Lung Cancer Liquid Biops Products, Services and Solutions
5.15.4 Trovagene Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.15.5 Trovagene Recent Developments
5.16 Fluxion Biosciences
5.16.1 Fluxion Biosciences Profile
5.16.2 Fluxion Biosciences Main Business
5.16.3 Fluxion Biosciences Lung Cancer Liquid Biops Products, Services and Solutions
5.16.4 Fluxion Biosciences Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.16.5 Fluxion Biosciences Recent Developments
5.17 Biodesix
5.17.1 Biodesix Profile
5.17.2 Biodesix Main Business
5.17.3 Biodesix Lung Cancer Liquid Biops Products, Services and Solutions
5.17.4 Biodesix Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.17.5 Biodesix Recent Developments
5.18 Epic Sciences
5.18.1 Epic Sciences Profile
5.18.2 Epic Sciences Main Business
5.18.3 Epic Sciences Lung Cancer Liquid Biops Products, Services and Solutions
5.18.4 Epic Sciences Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.18.5 Epic Sciences Recent Developments
5.19 Shuwen Biotech
5.19.1 Shuwen Biotech Profile
5.19.2 Shuwen Biotech Main Business
5.19.3 Shuwen Biotech Lung Cancer Liquid Biops Products, Services and Solutions
5.19.4 Shuwen Biotech Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.19.5 Shuwen Biotech Recent Developments
5.20 Personal Genome Diagnostics
5.20.1 Personal Genome Diagnostics Profile
5.20.2 Personal Genome Diagnostics Main Business
5.20.3 Personal Genome Diagnostics Lung Cancer Liquid Biops Products, Services and Solutions
5.20.4 Personal Genome Diagnostics Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.20.5 Personal Genome Diagnostics Recent Developments
5.21 Predicine
5.21.1 Predicine Profile
5.21.2 Predicine Main Business
5.21.3 Predicine Lung Cancer Liquid Biops Products, Services and Solutions
5.21.4 Predicine Lung Cancer Liquid Biops Revenue (US$ Million) & (2018-2023)
5.21.5 Predicine Recent Developments
6 North America
6.1 North America Lung Cancer Liquid Biops Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Lung Cancer Liquid Biops Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Liquid Biops Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Lung Cancer Liquid Biops Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Liquid Biops Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Lung Cancer Liquid Biops Market Dynamics
11.1 Lung Cancer Liquid Biops Industry Trends
11.2 Lung Cancer Liquid Biops Market Drivers
11.3 Lung Cancer Liquid Biops Market Challenges
11.4 Lung Cancer Liquid Biops Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
